Online Master's in Biomedical Engineering @ Case.edu
A Mighty Force - read full story

In The News

Newswise — CLEVELAND, Ohio --Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have preliminarily validated an artificial intelligence (AI) tool to predict how likely the disease is to recur following surgical treatment for prostate cancer. 

Anant Madabhushi, PhD, discusses how AI can be used to efficiently allocate healthcare resources by predicting response to treatment for COVID-19 patients.

Case Western Reserve and partners local and global team up to better predict which patients with oral squamous cell carcinomas will need radiation or chemotherapy after surgery

The agreement is the third partnership in 2020 between the CCIPD and leading biopharmaceutical companies to advance artificial intelligence (AI) tools for disease diagnosis and prognosis, as well as predicting response to therapy. In April, the CCIPD entered into a contract with AstraZeneca and earlier in the year had inked a similar deal with Bristol-Myers Squibb Company.

Researchers used AI to discover that coronavirus vaccines could be less effective for specific populations.

“Quality control for digital pathology slides” and “Vascular network organization via Hough transform (VaNgOGH): a radiomic biomarker for diagnosis and treatment response”. Congratulations to Anant Madabhushi, PhD, Donnell Institute Professor, biomedical engineering and Director of CCIPD; Andrew Janowczyk, PhD, research assistant professor, biomedical engineering and CCIPD, and alumni of CCIPD Nathaniel Braman, PhD and Prateek Prasanna, PhD.

“This idea [studying eye vasculature] is getting a variety of curiosity proper now,” Anant Madabhushi, PhD

Case Western Reserve University biomedical engineering leaders Scott Bruder, Anant Madabhushi honored for ‘spirit of innovation’

Radiomics analysis suggests underlying subvisual features may encode information related to tolerance of interval extension in retinal vascular disease

CCIPD’s Anant Madabhushi, PhD, and Pranjal Vaidya with collaborators Kaustav Bera, MD, and Vamsidhar Velcheti, MD, have been awarded US Patent #10,839,513, “Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic features.” 

Eight CCIPD abstracts will be presented during the United States and Canadian Academy of Pathology (USCAP) 110th Virtual Annual Meeting, held on March 13-18th, 2021. 

Case Western Reserve University (CWRU) invites applications for a mid-level faculty position in the area of artificial intelligence and medical imaging.  

Dr. Madabhushi will share the work of CCIPD in his talk titled, “Prognostic and Predictive Radiomics and Pathomics for Precision Oncology.”

“A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study.” 

 In this role, he will help advance digital health and Artificial Intelligence tools in medicine, supporting the FDA's mission to promote and protect public health.

Earlier this week, the second annual Artificial Intelligence in Oncology Symposium (AIO 2020) was held by the Case Comprehensive Cancer Center (Case CCC) and the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University.

SAIL hosted the October 21 virtual presymposium in advance of its scheduled in-person symposium in 2021. 

Join CCIPD and TIE Global on October 29th, 8am PDT, 11am EDT, 8:30pm IST, for a panel on “AI for Precision Oncology”